english.prescrire.org > Spotlight > Archives : 2019 > Dupilumab (Dupixent°) in adults with atopic dermatitis

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2019 : 1 | 30 | 60

In the May issue of Prescrire International: Dupilumab (Dupixent°) in adults with atopic dermatitis

FREE DOWNLOAD Dupilumab (Dupixent°), a monoclonal antibody, is an option for very troublesome eczema after failure of ciclosporin. Full text available for free download.

Summary

  • Atopic dermatitis (also called atopic eczema) is a chronic relapsing-remitting inflammatory skin condition. The severity of cutaneous symptoms and their impact on daily life vary greatly from one patient to another.
     
  • Dupilumab (Dupixent°, Sanofi Aventis) is a monoclonal antibody directed against the receptors for interleukins IL-4 and IL-13, which appear to be involved in the inflammatory response that occurs in atopic dermatitis. It has been authorised in the European Union for subcutaneous use in adults with moderate-to-severe atopic dermatitis, after failure of topical treatments.

  •  POSSIBLY HELPFUL  In patients with troublesome atopic dermatitis in whom topical treatments have failed, it has not been shown that dupilumab is at least as effective as ciclosporin or any other immunosuppressant...

Full text available for free download.

 ©Prescrire 1 May 2019

"Dupilumab (Dupixent°) in adults with atopic dermatitis. An option for very troublesome eczema after failure of ciclosporin" Prescrire Int 2019; 28 (204): 121. (Pdf, free).

Share Share on Facebook Share on Twitter
Share
Partager sur Facebook Partager sur Twitter

 
Download the full review
Pdf, free
Prescrire's rating:
Prescrire's rating
 POSSIBLY HELPFUL